(Tell me in the comments #ObesityMedicine #GLP1 #WeightManagement #FDAApproval #ClinicalPharmacy #MedicationAccess #PublicHealth #HealthEquity #ThePublicHealthPharmacist To view or add a comment, sign in The FDA has granted expedited approval to Eli Lilly's new weight-loss pill, orforglipron (Foundayo), marking it as the second daily oral GLP-1 medication for obesity
doi: 10.3748/wjg.v24.i30.3361 128 AnguloPKleinerDEDam-LarsenSAdamsLABjornssonESCharatcharoenwitthayaPet al
NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer
Overuse, dehydration, electrolyte imbalance, and long-term digestive issues are all possible
They work by mimicking the action of the GLP-1 hormone, which increases insulin secretion, decreases glucagon secretion, and slows gastric emptying
After kidney transplantation, TMAO levels decreased back to normal [21]